
Feature|Articles|December 23, 2025
- December 2025
- Volume 19
- Issue 4
Cancer Care and Education in the Era of Precision Oncology
Author(s)Linda Childers
Fact checked by: Bridget Hoyt, Tracy Ann Politowicz
Oncology nurses and APPs are key players in patient education on precision medicine.
Advertisement
Advertisement
In the era of precision oncology, nurses and advanced practice providers (APPs) do far more than manage chemotherapy or monitor adverse effects (AEs). Today’s cancer care requires a strong understanding of genetics and genomics, as these fields now drive how cancers are detected, treated, and even prevented. Genomic testing is routinely used to identify inherited cancer risks, guide screening strategies, and match patients with targeted therapies.
Related to this article

Erica L. Mayer, MD, MPH, explains what the all-oral giredestrant plus everolimus regimen asks of patients and oncology nurses between clinic visits.

The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.
Advertisement
Advertisement

